ZIA BC 010020 (ZIA) | |||
---|---|---|---|
Title | Clinical Trials with Immunotoxins | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Pastan, Ira | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $613,512 | Project Dates | 00/00/0000 - 00/00/0000 |
Fiscal Year | 2017 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Bioengineering (80.0%) Cancer (100.0%) Childhood Cancers (20.0%) Digestive Diseases (5.0%) |
Brain (5.0%) Childhood Leukemia (20.0%) Leukemia (20.0%) Lung (30.0%) Nervous System (5.0%) Non Hodgkins Lymphoma (20.0%) Ovarian Cancer (10.0%) Pancreas (5.0%) Prostate (5.0%) |
||
Research Type | |||
Vaccines Systemic Therapies - Clinical Applications |
|||
Abstract | |||
phase 3 trial evaluating its activity in patients with chemo-resistant hairy cell leukemia (HCL) has been completed. The response rate is very high with many complete and partial remissions lasting 6 months or more. There have been no major side effects. The data will be submitted to the FDA this year. For mesothelioma therapy we are evaluating a new genetically engineered immunotoxin (LMB-100) in patients with mesothelin expressing malignancies in collaboration with Drs. Raffit Hassan and Christine Alewine |